Clinical trials: Hemophagocytic Syndrome
EBV Infection
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown.
- Trial name
- SEHC (NCT05039580)
- Testing
- PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Hemophagocytic Syndromes
- Trial name
- FERRITS (NCT02854943)
- Volunteers
- 2,623 people
- Sponsor
- Gunnar Lachmann
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
PD-1 Antibody, Mixed Chimerism
PD-1 Antibody Improve Mixed Chimerism
PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape.
- Trial name
- HLH (NCT04944511)
- Testing
- Toripalimab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytoses
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
This study adopts an open-label, single-arm, multicenter design to evaluate the efficacy, safety, tolerability, immunogenicity, and PK characteristics of Plonmarlimab administration in patients with rheumatic and immunological…
- Trial name
- NCT07034209
- Testing
- Plonmarlimab
- Where
- 6 sites in China
- Volunteers
- 18 people
- Sponsor
- TJ Biopharma Co., Ltd.
Hemophagocytic Lymphohistiocytoses
Prospective Cohort for Adult Hemophagocytosis
This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis.
- Trial name
- NCT03117010
- Testing
- Steroids, Etoposide
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center
COVID
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia.
- Trial name
- COVIDHLH (NCT04347460)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Hemophagocytic Lymphohistiocytosis
Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
To evaluate the clinical value of splenectomy as a treatment for relapsed haemophagocytic lymphohistiocytosis (HLH) in patient with unknown etiology.
- Trial name
- NCT02862054
- Testing
- splenectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II.
- Conditions
- Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease
- Trial name
- NCT00006054
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fairview University Medical Center
Granulomatosis With Polyangiitis, Hemophagocytic Syndrome
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male…
- Trial name
- NCT05353179
- Testing
- Meperizumab injection, NUCALA®
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Rituximab Monotherapy for EBV-HLH and CAEBV
This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV…
- Trial name
- NCT05384743
- Testing
- Rituximab Monotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
This study aimed to investigate the efficacy and safety of different doses of ruxolitinib as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).
- Trial name
- NCT04120090
- Testing
- low dose ruxolitinib, high dose ruxolitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Friendship Hospital
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- PRO-RIC (NCT04528355)
- Testing
- data collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Paul Szabolcs
Hemophagocytic Lymphohistiocytosis
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures.
- Trial name
- TIC-TAC-SAM (NCT07497438)
- Testing
- Etoposide (Early strategy), Etoposide (Delayed strategy)
- Where
- France
- Volunteers
- 176 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
EBV Infection
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus.
- Trial name
- NCT03491605
- Testing
- peripheral EBV-DNA load
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Huazhong University of Science and Technology
Hemophagocytic Lymphohistiocytosis
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the…
- Trial name
- HELA2012 (NCT01547143)
- Testing
- IST and/or alloHCT
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Hemophagocytic Lymphohistiocytosis (HLH)
Treatment of Familiar Lymphohistiocytosis
The purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab
- Trial name
- C-HLH (NCT02472054)
- Testing
- Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis
Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH)
Rationale/Gaps in Existing Knowledge: Therapy of Infection-associated Secondary Hemophagocytic lymphohistiocytosis (sHLH) in adult lacks evidence from randomized trial guiding first-line immunomodulation and current therapeutic…
- Trial name
- isHLH-IVD/IVIg (NCT07861776)
- Testing
- Intravenous Immunoglobulin (IVIg) therapy, Intravenous Dexamethasone (IVD) therapy, Targeted antimicrobial therapy & standard care
- Volunteers
- 116 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hemophagocytic Lymphohistiocytosis (HLH)
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation.
- Trial name
- HSCT-HLH (NCT07905066)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital